
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDE-397,Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA Expands IDE397-Trodelvy Study for MTAP-Deleted Urothelial Cancer
Details : IDE397 is first-in-class, small molecule MAT2A inhibitor, being evaluating in combination with Trodelvy in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : IDE-397,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
